Navigation Links
BioCryst Announces Initiation of Phase II Study of Intramuscular Peramivir for the Treatment of Seasonal Influenza
Date:7/10/2008

BIRMINGHAM, Ala., July 10 /PRNewswire-FirstCall/ -- BioCryst Pharmaceuticals, Inc. (Nasdaq: BCRX) today announced the initiation of a Phase II study of intramuscular (i.m.) peramivir for the treatment of seasonal influenza.

The double-blind, placebo-controlled, parallel group Phase II trial will compare the efficacy of a single 600 mg injection of i.m. peramivir to placebo in the treatment of seasonal influenza. The dose was selected based upon an analysis of a recently completed Phase I study of a new, more concentrated 150 mg/ml formulation of i.m. peramivir, as well as prior studies of peramivir in patients with influenza. The Phase II study will utilize the new, more concentrated 150 mg/ml formulation and needle length guidelines established in recently conducted pharmacokinetic studies.

The primary endpoint of BioCryst's Phase II trial is improvement in time to alleviation of symptoms in patients. Secondary endpoints include reduction in viral titers and safety and tolerability. The trial is expected to enroll approximately 320 patients and will be conducted in the Southern Hemisphere.

"Conducting this study with our new, more concentrated formulation allows us to test peramivir in the outpatient setting at a higher dose than previously evaluated," stated Jon P. Stonehouse, President and Chief Executive Officer of BioCryst. "We are confident the results of this study will move us one step closer to offering a novel and important therapeutic option for the treatment of influenza infections."

About BioCryst

BioCryst Pharmaceuticals, Inc. is a leader in the use of crystallography and structure-based drug design for the development of novel therapeutics to treat cancer, cardiovascular diseases, autoimmu
'/>"/>

SOURCE BioCryst Pharmaceuticals, Inc.
Copyright©2008 PR Newswire.
All rights reserved

Page: 1 2 3 4

Related medicine technology :

1. BioCryst Initiates Enrollment in Pivotal Trial of Forodesine HCL in Patients with Cutaneous T-Cell Lymphoma (CTCL)
2. BioCryst Provides Forodesine HCl Update
3. BioCryst Updates Peramivir Clinical Development Plan
4. Dendreon Announces Publication of Phase 1 Study Highlighting Immunologic and Clinical Activity of Lapuleucel-T (Neuvenge(R)) in Advanced Breast Cancer Patients
5. EDAP Announces Launch of Clinical Study Combining HIFU and Chemotherapy for Localized Aggressive High Risk Prostate Cancer
6. Cephalon Announces Positive Results from a Pivotal Study of FENTORA in Opioid-tolerant Patients with Non-cancer Breakthrough Pain
7. ADVENTRX Announces Fast Track Designation Granted By the FDA For CoFactor For the Treatment of Metastatic Colorectal Cancer
8. DOV Pharmaceutical, Inc. Announces Successful Phase Ib Results for DOV 21,947
9. Phosphagenics Announces Positive Phase 1b Transdermal Insulin Clinical Trial Results
10. Xenomics Announces Implementation of its First Diagnostic Test for Acute Myeloid Leukemia Into Clinical Practice
11. Emisphere Technologies, Inc. Announces 2007 Second Quarter Financial Results
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:12/19/2014)... 2014 Research and Markets ( ... "Micro Market Monitor: North American Dermatology Diagnostic ... http://photos.prnewswire.com/prnh/20130307/600769 ... which has resulted in fueling the overall demand ... purpose of these dermatology devices is to assist ...
(Date:12/19/2014)... Baptist Health Lexington is the first facility in ... Atrial Fibrillation with Electrophysiology Services (EPS) Accreditation status from the ... is the most common cardiac arrhythmia and has become recognized ... to stroke and possible death. More than 5 million patients ... fibrillation and the numbers are rapidly increasing as the population ...
(Date:12/17/2014)... AMSTERDAM and SAN DIEGO , ... PHG ; AEX: PHIA) and Volcano Corporation (NASDAQ: ... and measurement solutions for cardiovascular applications, today announced that they ... agreement, Philips will commence a tender offer to acquire all ... 18.00 per share, or a total equity purchase price of ...
Breaking Medicine Technology:Micro Market Monitor: North American Dermatology Diagnostic Devices Market 2Micro Market Monitor: North American Dermatology Diagnostic Devices Market 3Baptist Health Lexington First in the Nation to Receive Atrial Fibrillation with EPS Accreditation 2Baptist Health Lexington First in the Nation to Receive Atrial Fibrillation with EPS Accreditation 3Philips to acquire Volcano to expand global leadership position in image-guided therapy market 2Philips to acquire Volcano to expand global leadership position in image-guided therapy market 3Philips to acquire Volcano to expand global leadership position in image-guided therapy market 4Philips to acquire Volcano to expand global leadership position in image-guided therapy market 5Philips to acquire Volcano to expand global leadership position in image-guided therapy market 6Philips to acquire Volcano to expand global leadership position in image-guided therapy market 7Philips to acquire Volcano to expand global leadership position in image-guided therapy market 8
... MOUNTAIN VIEW, Calif., April 4, 2011 VIVUS, Inc. (Nasdaq: ... patients treated with the investigational drug QNEXA® for two years ... medications as well as improvements in lipid levels following significant ... placebo group over two years. The data ...
... community pharmacy chain, has revealed that one in four* (24%) of ... has taken or applied medicines which they later discovered were out ... (53%) of people do not always check the expiry date of ... This is worrying considering that nearly one in ...
Cached Medicine Technology:Weight Loss With QNEXA® Over Two Years Provides Patients With Substantial Cardiovascular Benefits 2Weight Loss With QNEXA® Over Two Years Provides Patients With Substantial Cardiovascular Benefits 3Lloydspharmacy Reveals Over 11 Million Britons Risking Health by Taking Old Medicines 2Lloydspharmacy Reveals Over 11 Million Britons Risking Health by Taking Old Medicines 3
(Date:12/19/2014)... Sweetdressy.com , a leading wedding dress manufacturer ... of cheap prom dresses for ladies worldwide. The prom ... and clients can buy these dresses at the website ... cool cuts and delicate craftsmanship, and most of them ... Discount shipping costs are available for all of their ...
(Date:12/19/2014)... Branson, Missouri (PRWEB) December 19, 2014 ... a new official world record -- for the first time ... most prestigious record book, Guinness World Records 2015, listing the ... Steepest Wooden Roller Coaster. In additional awards announced this week, ... to See Christmas Lights in the US,” USA Today’s 10Best ...
(Date:12/19/2014)... dress is perfect for any occasion and is a vital ... has unveiled its new selection of evening dresses. Faddish clients ... Customers can view more at its website. , ... and praised by customers for many years. It focuses on ... order to expand its market share, the company has opened ...
(Date:12/19/2014)... 19, 2014 (HealthDay News) -- The intestinal bacteria that ... ulcerative colitis, may be inherited, researchers report. The ... , could help in efforts to prevent the disease ... colitis, the study authors added. "The intestinal bacteria, ... age can have a big impact on your health ...
(Date:12/19/2014)... News) -- Dense bunches of bacteria called biofilms can be ... finds. The researchers said these biofilms were especially ... presence of these biofilms may represent an increased likelihood of ... a person,s risk for the disease, the researchers said. ... may coat the mucus layer of cells lining the colon, ...
Breaking Medicine News(10 mins):Health News:Cheap Prom Dresses Online Now at Sweetdressy.com 2Health News:Silver Dollar City Nets New Titles: Guinness Book of World Records, Plus CNN Travel, USA Today & Fodor’s Top Places for Christmas Lights 2Health News:Attractive Evening Dresses Announced by Discount-Dress.com 2Health News:Crohn's, Colitis May Have Genetic Underpinnings, Study Finds 2Health News:Could Bacteria Play a Role in Colon Cancer? 2
... Inc.,publicly announces its offering of patient safety culture and ... clients since 2007,Pascal Metrics rapidly has become a worldwide ... other regulatory requirements, to reduce,costs, and - by making ... failure and errors. , ...
... Technologies(R), Inc.,("Global Med" or the "Company") (OTC ... technology company, today announced that its,European subsidiary, ... marketed as "Hemo Serveur" in France, to ... hospitals, representing 23,000 patient beds. For,Global Med, ...
... Parents and Professionals Shares Experience , Dealing ... , WASHINGTON, Dec. 2 ... equity, diversity, and quality of life for people with ... -- a free peer-to-peer resource directory accessible to ...
... show it could aid shift workers, people affected by jet ... drug tasimelteon helps treat temporary insomnia caused by jet lag ... clinical trials. , The phase II study included 39 people ... mg or 100 mg of tasimelteon, or a placebo. They ...
... ORLANDO, Fla., Dec. 2 MEDai, Inc., headquartered ... added a new module,to its existing suite of ... a population,s compliance to evidence-based medicine,guidelines and alerts ... protocol. The module Risk Navigator Guidelines(TM) provides,real-time ...
... Skipped Medical Care Due to Cost Issues- , ... survey released today by the National Women,s Health Resource Center (NWHRC) ... have failed to seek health care for themselves or their families ... their health has gotten worse over the past five years and ...
Cached Medicine News:Health News:Pascal Metrics Announces Patient Safety Culture Services Offering 2Health News:Global Med Technologies(R)' European Subsidiary to Provide Strategic Blood Transfusion Software for 21 Paris Hospitals 2Health News:Global Med Technologies(R)' European Subsidiary to Provide Strategic Blood Transfusion Software for 21 Paris Hospitals 3Health News:Global Med Technologies(R)' European Subsidiary to Provide Strategic Blood Transfusion Software for 21 Paris Hospitals 4Health News:New Website Links People With Disabilities to Peers for Help 2Health News:Drug Effective for Temporary Sleep Disruptions 2Health News:MEDai Evidence-Based Guideline Reporting Provides Decision Support at Point of Care 2Health News:Rising Health Costs Prompt Women to Neglect Health 2Health News:Rising Health Costs Prompt Women to Neglect Health 3Health News:Rising Health Costs Prompt Women to Neglect Health 4
... Mesh is constructed of Bard polypropylene mesh, ... over 40 years. Developed with the world ... Preshaped Mesh takes the guesswork out of ... sugeon performs a Lichtenstein inguinal hernia repair ...
... Kugel patch repair is a minimally invasive, ... a small 4-6 cm incision and requires ... performed through an open, anterior approach that ... anesthesia.,The Modified Kugel patch is a self-expanding ...
... PerFix plug technique, recommended for the ... indirect and direct inguinal hernias, provides ... technique, requiring less overall dissection and ... repair technique. The result is increased ...
... is constructed of knitted filaments of ... that used in PROLENE* Polypropylene Suture, ... The mesh is approximately,0.020 inches thick. ... suture, has been reported to be ...
Medicine Products: